Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 5/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.58 |
| ▸ | CCR2 | P41597 | 15/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.42 |
| ▸ | CCR4 | P51679 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | CCR9 | P51686 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1762449 | 0.94 | CYP2C9 (0.64) | CYP2C9CYP3A4CCR2CYP2C19CCR4 | |
| SCHEMBL1762485 | 0.93 | CYP2C9 (0.68) | CYP2C9CYP3A4CCR2CYP2C19CCR4 | |
| SCHEMBL306637 | 0.92 | CYP2C9 (0.77) | CYP2C9CYP3A4CCR2 | |
| SCHEMBL1762514 | 0.89 | CYP2C9 (0.61) | CYP2C9CYP3A4CCR2CYP2C19CCR4 | |
| SCHEMBL1762314 | 0.89 | CYP2C9 (0.58) | CYP2C9CYP3A4CCR2CYP2C19CCR4 | |
| SCHEMBL12648498 | 0.88 | CYP2C9 (0.57) | CYP2C9CYP3A4CCR2CYP2C19CCR4 | |
| SCHEMBL1762431 | 0.87 | CYP2C9 (0.57) | CYP2C9CYP3A4CCR2CYP2C19CCR4 | |
| SCHEMBL1762492 | 0.87 | CYP2C9 (0.57) | CYP2C9CYP3A4CCR2CYP2C19CCR4 | |
| SCHEMBL1762423 | 0.87 | CYP2C9 (0.56) | CYP2C9CYP3A4CCR2CYP2C19CCR4 | |
| SCHEMBL306072 | 0.87 | CYP2C9 (0.65) | CYP2C9CYP3A4CCR2CYP2C19CCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263784-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CHEMOCENTRYX, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230263784-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CHEMOCENTRYX, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-20210346361-A1 | METHODS OF TREATING SOLID TUMORS WITH CCR2 ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-11-11 | — | — | US | disclosed |
| WO-2020191240-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1 AND/OR PD-L1 INHIBITOR | CHEMOCENTRYX, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| US-20200297708-A1 | Combination Therapy Using a Chemokine Receptor 2 (CCR2) Antagonist and a PD-1 and/or PD-L1 Inhibitor | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-09-24 | — | — | US | disclosed |
| US-20200147066-A1 | Heteroaryl Sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. | 2020-05-14 | — | — | US | disclosed |
| US-20200147066-A1 | Heteroaryl Sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. | 2020-05-14 | — | — | US | disclosed |
| US-20190275015-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CHEMOCENTRYX, INC. | 2019-09-12 | — | — | US | disclosed |
| US-20140031348-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX INC (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031348-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX INC (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031348-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX INC (US) | 2014-01-30 | — | — | US | disclosed |
| US-8519135-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8519135-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8519135-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20110118248-A1 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. | 2011-05-19 | — | — | US | disclosed |
| US-20110118248-A1 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. | 2011-05-19 | — | — | US | disclosed |
| US-20110118248-A1 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. | 2011-05-19 | — | — | US | disclosed |
| WO-2008008431-A2 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346361-A1 | METHODS OF TREATING SOLID TUMORS WITH CCR2 ANTAGONISTS | CCR2, CXCR2, CCRL2 | CYP2C9 3132/4885CYP3A4 3623/4885CCR2 1/4885 |
| US-20190275015-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CCR2, PDCD1LG2, CD274 | CYP2C9 3501/4885CYP3A4 3935/4885CCR2 1/4885 |
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | CYP2C9 192/4885CYP3A4 1934/4885CCR2 1/4885 |
| US-20200297708-A1 | Combination Therapy Using a Chemokine Receptor 2 (CCR2) Antagonist and a PD-1 and/or PD-L1 Inhibitor | PDCD1LG2, CCR2, CD274 | CYP2C9 4045/4885CYP3A4 4440/4885CCR2 2/4885 |
| US-20140031348-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CCR2, CCR9, CCR1 | CYP2C9 192/4885CYP3A4 1934/4885CCR2 1/4885 |
| US-20200147066-A1 | Heteroaryl Sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | CYP2C9 192/4885CYP3A4 1934/4885CCR2 1/4885 |
| US-20110118248-A1 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | CYP2C9 192/4885CYP3A4 1934/4885CCR2 1/4885 |
| US-20230263784-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CCR2, PDCD1LG2, CD274 | CYP2C9 3501/4885CYP3A4 3935/4885CCR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.